Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model

Resiquimod is an immunopotent toll-like receptor 7/8 agonist with anti-tumor activity. Despite being potent against skin cancers, it’s poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Healthc Mater
Autors principals: Kakwere, Hamilton, Zhang, Hua, Ingham, Elizabeth S., Nura-Raie, Marina, Tumbale, Spencer K., Allen, Riley, Tam, Sarah M., Wu, Bo, Liu, Cheng, Kheirolomoom, Azadeh, Fite, Brett Z., Ilovitsh, Asaf, Lewis, Jamal S., Ferrara, Katherine W.
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153207/
https://ncbi.nlm.nih.gov/pubmed/33646600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202100008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars